Emerging Stocks Down Under 17 January 2023: Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals: FDA approval likely coming soon

There are very few Biotechs that have more than doubled in the last year. Neuren Pharmaceuticals, however, is one such company. The company’s flagship asset Trofinetide – also known as NNZ-2566 – has passed all clinical trial phases and is being examined by the FDA as a candidate drug to treat Rett Syndrome, a rare neurological disorder. A regulatory decision is due in the next couple of months and we think shareholders can be optimistic about the prospects of approval. We also think that Trofinetide’s approval for Rett Syndrome can be just the beginning for this company’s prospects, considering it has other candidate drugs in the clinic as well.


Click here to read the previous edition of Emerging Stocks Down Under published 10 January 2023.

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.